BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Manufacture of Synthetic Ibogaine Moves to Second Stage

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has begun the second stage of manufacturing pharmaceutical-grade ibogaine to be used in clinical research. According to the announcement, this stage will focus on assessing the quality of MINDCURE’s synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing. The company intends to manufacture pharmaceutical-grade ibogaine to provide researchers with a consistent supply of sustainable, high-quality, reliable psychedelic substance. The company has already filed patent applications for two routes of chemical synthesis of ibogaine, with both options showing potential to provide synthetic ibogaine with improved isomeric purity, increased purity and more easily isolated intermediate compounds; MINDCURE is in the process of assessing which method to develop further. The psychoactive substance ibogaine is found naturally in the roots of the iboga tree, which grows in Africa, and has been shown to influence pain, addiction and neurodegenerative conditions. In addition to providing outside researchers with a consistent supply of pharmaceutical-grade ibogaine, MINDCURE’s own research team will also use the drug in its development studies. “We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes,” said Mind Cure Health president and CEO in the press release. “We are currently working on proving the ability to scale up the production, and our next step will be to test the ibogaine to ensure it meets the highest standards of pharmaceutical grade product.”

To view the full press release, visit https://ibn.fm/jDr7c

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.  

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork